Lumos Pharma to Report Full Year 2023 Financial Results and Host Conference Call on March 7, 2024
Lumos Pharma to Report Full Year 2023 Financial Results and Host Conference Call on March 7, 2024
AUSTIN, Texas, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced it will report its full year 2023 financial results after market close on Thursday, March 7, 2024. The company will host a conference call and webcast at 4:30 PM ET that day to discuss these financial results and provide an update on clinical and corporate activities. A question-and-answer session will follow the prepared remarks.
得克萨斯州奥斯汀，2024年2月26日（GLOBE NEWSWIRE）——通过2期临床试验推进儿科生长激素缺乏症（PGHD）口服疗法候选药物的生物制药公司Lumos Pharma, Inc.（纳斯达克股票代码：LUMO）宣布将在2024年3月7日星期四收盘后公布其2023年全年财务业绩。该公司将在美国东部时间当天下午 4:30 举行电话会议和网络直播，讨论这些财务业绩，并提供临床和公司活动的最新情况。在准备好的发言之后，将举行问答环节。
Investors and the general public are invited to listen to the conference call. To access the call by phone, please click on this Registration Link, complete the form and you will be provided with dial in details and a PIN. To avoid delays, we encourage participants to dial into the conference call ten minutes ahead of the scheduled start time. The webcast may be accessed through this Webcast Link and may also be found in the "Investors & Media" section of the Lumos Pharma website, under "Events & Presentations." A replay of the call will be available after the date of the call and may be accessed through the same link above or found on our website.
邀请投资者和公众收听电话会议。要通过电话接听电话，请点击此注册链接，填写表格，您将获得拨入详细信息和 PIN 码。为避免延误，我们鼓励参与者在预定开始时间前十分钟拨打电话会议。可以通过此网络直播链接访问网络直播，也可以在Lumos Pharma网站的 “投资者与媒体” 部分的 “活动与演讲” 下找到。电话会议的重播将在通话日期之后提供，可以通过上面的相同链接进行访问，也可以在我们的网站上找到。
About Lumos Pharma
关于 Lumos Phar
Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. The Company was founded and is led by a management team with longstanding experience in rare disease drug development. Lumos Pharma's lead therapeutic candidate, LUM-201, is a novel, oral growth hormone (GH) secretagogue, seeking to transform the ~$3.4B global GH market from injectable to oral therapy. LUM-201 is currently being evaluated in multiple Phase 2 clinical studies in Pediatric Growth Hormone Deficiency (PGHD) and has received Orphan Drug Designation in both the US and EU. For more information, please visit
Lumos Pharma, Inc. 是一家临床阶段的生物制药公司，专注于罕见疾病疗法的开发和商业化。该公司成立并由一支在罕见病药物开发方面具有长期经验的管理团队领导。Lumos Pharma的主要候选治疗药物 LUM-201 是一种新型的口服生长激素（GH）促分泌剂，旨在将全球约34亿美元的生长激素市场从注射剂转变为口服疗法。LUM-201 目前正在多项儿科生长激素缺乏症 (PGHD) 的 2 期临床研究中接受评估，并已在美国和欧盟获得孤儿药认定。欲了解更多信息，请访问
Investor & Media Contact:
投资者和媒体联系人：
Lisa Miller
Lumos Pharma Investor Relations
512-792-5454
ir@lumos-pharma.com
丽莎米勒
Lumos Parma 投资者关系
512-792-5454
ir@lumos-pharma.com
Source: Lumos Pharma, Inc.
资料来源：Lumos Pharma, Inc.